FEATURE ARTICLES
Many manufacturing execution system (MES) deployments still operate like it is 2005: a big install, disruptive upgrades, etc. Here's a clearer path forward.
- A Peek Into Novo Nordisk's Sustainable Facility Construction Mindset
- Tackling OSD Manufacturing Challenges With Pharma 4.0 Digital Innovation: Overview
- At Base Camp: Lilly's Manufacturing Capacity Journey
- The U.S. Has A New Vice To Squeeze Foreign Imports: Pharma Quality
- January 2026 — CDMO Opportunities And Threats Report
- Solving The Top 3 Pharma Packaging/Manufacturing Issues
- New ISPE Framework Targets Uncertainty In Pharma's AI Deployment
PHARMA ONLINE WHITE PAPERS
-
![getty-1311598658-data-analytics]( "Enabling Quality By Design")
Enabling Quality By DesignOutdated quality systems delay product release. Discover how manufacturers can harness real-time data, operationalize QbD, and enhance compliance, efficiency, and supply chain continuity.
-
Calcium Carbonate Vs Titanium Dioxide: Why Particle Engineering Matter11/10/2025
Discover how particle-engineered calcium carbonate offers a viable alternative to titanium dioxide in tablet coatings, achieving good opacity, process efficiency, and comparable tablet properties.
-
Placing Drug Strategies On A Solid Foundation For Success9/3/2025
Explore how certain drivers are impacting traditional drug development strategies and relationships with outsourced drug development and manufacturing partners.
-
Transitioning Your Product From Phase 1 To Phase 2 Clinical Studies12/13/2024
Strategic partnerships can streamline your transition from Phase 1 to Phase 2 clinical studies, ensuring optimized dosage forms, seamless scale-up, and alignment with patient and study requirements.
-
Opportunities In Preclinical Development11/4/2024
Every domain produces critical data and this data and contexual information should be captured and managed in the most effective and robust manner.
-
Continuous Manufacturing For API Breakthroughs7/31/2025
Observe how a compound library, designed for chemical diversity and lead-like properties, uses advanced filtering to improve hit discovery, speed hit-to-lead development, and boost early-stage small molecule drug discovery.
PHARMA ONLINE APP NOTES & CASE STUDIES
NEWSLETTER ARCHIVE
- 02.20.26 -- Lessons In Quality From Sanofi's Plai.qa
- 02.19.26 -- STREAM Edition: Regulatory Guidance For Cleaning And Disinfecting
- 02.18.26 -- How To Break Through Fill/Finish Bottlenecks
- 02.17.26 -- Solving The Top 3 Pharma Packaging/Manufacturing Issues
- 02.16.26 -- Cutting‑Edge Tools Transforming Drug Manufacturing In 2026
INDUSTRY NEWS
-
![FDA Logo on phone screen-GettyImages-2208861549]( "Høeg In, Pazdur Out At The FDA")
Høeg In, Pazdur Out At The FDAWhat an eventful week it has been at the FDA, with Richard Pazdur, M.D., resigning after weeks in his position as director of Center for Drug Research and Evaluation (CDER), and his vacancy being quickly filled by acting director Tracy Beth Høeg, M.D.
-
![business peope negotiating-GettyImages-637902194]( "9 Drugs Granted Fast Track By FDA's Voucher Program")
9 Drugs Granted Fast Track By FDA's Voucher ProgramWith targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.
-
![Pharmaceutical sorting machine, pills-GettyImages-1499814881]( "Leaders In The Excipient Market: Region And Type")
Leaders In The Excipient Market: Region And TypeThough North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.
-
![GettyImages-2189405678-GLP-1-obesity]( "Pfizer Strengthens Obesity Foothold With Metsera Acquisition")
Pfizer Strengthens Obesity Foothold With Metsera AcquisitionAfter discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.
-
![weight loss, diabetes, insulin pen-GettyImages-2196049931]( "FDA Cracks Down On GLP-1 Imports")
FDA Cracks Down On GLP-1 ImportsGLP-1 bulk drug substances must be detained without physical examination (DWPE) unless they are on a list (Green List) of approved foreign GLP-1 manufacturers.
PHARMACEUTICAL ONLINE CONTENT COLLECTIONS
Explore how sterility assurance, including sterilization validation and environmental monitoring, is essential for controlling microbial contamination in mammalian cell production to ensure patient safety. Check out the latest e-book from Pharmaceutical Online.
More Content CollectionsSUPPLIER NEWS
-
Syntegon Launches AIM9 High-Speed Inspection Platform2/18/2026
Based on decades of experience and proven technology, Syntegon is launching the AIM9 inspection platform. It combines visual inspection and leak detection with outputs of up to 600 vials per minute, helping pharmaceutical manufacturers and CMOs achieve the highest inspection and product quality.
-
JHS CEO Chris Preti Receives 2026 Person Of Influence Award2/12/2026
Spokane, WA. - The Spokane Journal of Business named Chris Preti, CEO of Jubilant HollisterStier (JHS), as one of its 2026 People of Influence.
-
Subcutaneously Administered Nanotrastuzumab Matches Performance Of Herceptin HYLECTA In Minipig Study2/12/2026
Nanoform Finland Plc, the medicine performance-enhancing company, announced the results from a preclinical study designed to compare the tolerability and pharmacokinetics of Nanotratsuzumab, a nanoformed, novel, hyaluronidase-free, non-aqueous nanoparticle suspension of trastuzumab for subcutaneous delivery versus Herceptin HYLECTA™, a co-formulated product with Halozyme’s proprietary hyaluronidase enzyme marketed by Roche/Genentech.
-
A New Chapter In ROIS Commercial Leadership2/11/2026
ROIS today announced the appointment of Kimberlee Steele as Chief Commercial Officer, effective from 1 March 2026.
